EMA blesses ovarian cancer use for Roche's Avastin

Roche's Avastin won a new indication in ovarian cancer in Europe. The European Medicines Agency approved the drug for use in patients with newly diagnosed, advanced ovarian cancer, in combination with chemotherapy. Report

Suggested Articles

CG image of AstraZeneca's HQ
Pharma

AZ's Calquence posts sky-high CLL survival numbers

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

by Carly Helfand
fighting
Marketing

Keytruda's bladder cancer gene therapy rival wins in phase 3

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

by Angus Liu
Novartis headquarters
Pharma

FDA greenlights generics of Novartis' $3B MS star Gilenya

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

by Arlene Weintraub